Company news

Precigen, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

March 4, 2024

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 5, 2024

Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

January 15, 2024

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

January 7, 2024

Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 17, 2023

Precigen to Participate in the JMP Securities Hematology and Oncology Summit

November 28, 2023

Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs

November 8, 2023

Precigen to Participate in the Stifel 2023 Healthcare Conference

November 6, 2023

Precigen to Participate in Upcoming Leading Investor and Industry Conferences

September 18, 2023

Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025

August 8, 2023

Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

August 8, 2023

Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th

August 2, 2023

Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

June 19, 2023

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

June 4, 2023

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers

June 2, 2023

Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer

May 30, 2023

Precigen Reports First Quarter 2023 Financial Results and Business Updates

May 9, 2023

Precigen to Announce First Quarter 2023 Financial Results on May 10th

May 2, 2023

Precigen to Present Latest Clinical Advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 Off-the-Shelf AdenoVerse™ Immunotherapy at the 2023 ASCO Annual Meeting

April 25, 2023

Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023

April 16, 2023

Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T®

April 2, 2023

Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors

March 28, 2023

Precigen to Participate in a Virtual Fireside Chat at Cantor's "The Future of Oncology" Virtual Symposium

March 27, 2023

Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

March 5, 2023

Precigen Is Pioneering a Nonsurgical Treatment for a Debilitating Respiratory Disease; Positive Data Released on Recurrent Respiratory Papillomatosis Showed a 50% Complete Response

February 6, 2023

Precigen Announces Closing of Public Offering of Common Stock

January 26, 2023

Precigen Announces Proposed $75.0 Million Public Offering of Common Stock

January 23, 2023

Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock

January 23, 2023

Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis

January 23, 2023

Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

January 10, 2023

Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse™ Immunotherapy in Recurrent Respiratory Papillomatosis

January 3, 2023

Precigen to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 18, 2022

Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients

December 11, 2022

Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs

November 8, 2022

Precigen to Announce Third Quarter 2022 Financial Results on November 9th

November 1, 2022

Precigen Names Rutul R. Shah Chief Operating Officer

September 20, 2022

Precigen to Participate in the 2022 Wells Fargo Healthcare Conference

August 31, 2022

Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics

August 21, 2022

Precigen Reports Second Quarter and First Half 2022 Financial Results

August 7, 2022

Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th

July 31, 2022

Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics

July 4, 2022

Precigen to Participate in the Stifel 2022 Virtual Cell Therapy Summit

June 26, 2022

Precigen to Participate in the 2022 H.C. Wainwright Global Investment Conference

May 16, 2022

Precigen Reports First Quarter 2022 Financial Results and Business Updates

May 8, 2022

Precigen Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia

April 3, 2022

Precigen Reports Fourth Quarter and Full Year 2021 Financial Results

February 28, 2022

Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference

January 11, 2022

Precigen to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 4, 2022

Precigen Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Leukemia

December 12, 2021

Precigen to Present at the Stifel 2021 Virtual Healthcare Conference

November 9, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 34 decks. Every deck is listed under its year.